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Abstract
Proteasome inhibitors are emerging as a new class of cancer therapeutics, and bortezomib has shown promise in
the treatment of multiple myeloma and mantle cell lymphoma. However, bortezomib has failed to have an effect in
preclinical models of glioma. NPI-0052 is a new generation of proteasome inhibitors with increased potency and
strong inhibition of all three catalytic activities of the 26S proteasome. In this article, we test the antitumor efficacy
of NPI-0052 against glioma, as a single agent and in combination with temozolomide and radiation using five dif-
ferent glioma lines. The intrinsic radiation sensitivities differed for all the lines and correlated with their PTEN ex-
pression status. In vitro, NPI-0052 showed a dose-dependent toxicity, and its combination with temozolomide
resulted in radiosensitization of only the cell lines with a mutated p53. The effect of NPI-0052 as a single agent
on glioma xenografts in vivo was only modest in controlling tumor growth, and it failed to radiosensitize the glioma
xenografts to fractionated radiation. We conclude that NPI-0052 is not a suitable drug for the treatment of malig-
nant gliomas despite its efficacy in other cancer types.
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Introduction
Malignant gliomas are among the most aggressive solid tumors in hu-
mans. After debulking surgery and radiotherapy, the median survival
is approximately 12 months. The only drug shown to be effective in
combination with radiotherapy is temozolomide. However, when
combined with radiotherapy after surgery, the increase in median sur-
vival is only 2 months [1]. These disappointing results have moti-
vated the search for novel treatment options and drug combinations.
The 26S proteasome is a multicatalytic protease complex with
at least three distinct proteolytic activities (chymotryptic, tryptic,
caspase-like). It degrades almost all short-lived and almost all long-
lived proteins in eukaryote cells in an ubiqutin-dependent fashion
[2–4]. This protease is a key regulatory hub for many signal trans-
duction pathways altered in cancer and is involved in cell death and
DNA repair [5]. Consequently, specific inhibitors of this protease
were introduced into cancer treatments, and bortezomib, a specific
inhibitor of the chymotryptic activity of the proteasome has been
approved for the treatment of patients with multiple myeloma or
mantle cell lymphoma [6,7]. Although bortezomib has excellent anti-
tumor activity in preclinical in vitro and in vivo models, it has shown
poor clinical efficacy against solid cancers as a single agent or in com-
bination with established chemotherapeutic drugs [8–10]. A recent
phase 1 trial in glioma combining bortezomib with temozolomide
and radiation in glioma did not show any additional benefit for pa-
tients treated with bortezomib [10].
NPI-0052 (salinosporamide A) is a novel proteasome inhibitor [11]
that targets all three activities of the 26S proteasome [12], thus making
it a more effective inducer of cancer cell death than bortezomib [13].
Therefore, clinical trials using NPI-0052 have been initiated for the
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treatment of multiple myeloma patients [14]. Given that bortezomib
has failed to demonstrate a beneficial effect in gliomas [10], we tested
if the enhanced potency of NPI-0052 translated into antitumor
activity, as a single agent or in combination with temozolomide and
radiation, the current standard therapy for this disease [15]. We hy-
pothesized that NPI-0052 combined with radiation and temozolomide
would be effective against glioma cells in vitro and in vivo. However,
although NPI-0052 induced cell death in vitro, it failed to consistently
radiosensitize glioma cells in vitro and did not synergize with radia-
tion in vivo.
Materials and Methods
Cell Culture
The U87MG glioma cell line and the GBM-ES and GBM-RW
primary glioma cultures were a kind gift from Dr P. Michel (Depart-
ment of Pathology, UCLA). The GBM-2345 and GBM-177 primary
glioma lines were a kind gift from Dr Kornblum (Department of
Molecular and Medical Pharmacology, David Geffen School of Med-
icine at UCLA). All the cells were cultured in log-growth phase in
Dulbecco’s modified Eagle medium (DMEM)–F12 (Invitrogen,
Grand Island, NY) (supplemented with 10% heat-inactivated fetal
bovine serum (Sigma, St. Louis, MO), penicillin (100 U/ml), and
streptomycin (100 μg/ml) cocktail) and were grown at 37°C in a hu-
midified atmosphere (5% CO2). To obtain single-cell suspensions for
further assays, cells were dissociated with trypsin-EDTA (Invitrogen),
pelleted by centrifugation, and resuspended in DMEM-F12 medium
and replated.
Western Blot Analysis
The proteins were separated by SDS-PAGE and then transferred
to polyvinylidene fluoride membranes (BioRad, Hercules, CA). Blots
were blocked and then probed with antibodies against epidermal
growth factor receptor (EGFR, 1:1000 dilution; Abcam, Cambridge,
MA), p53 (1:200 dilution; EMD Biosciences, Gibbstown, NJ), O6-
methylguanine-DNA methyltransferase (MGMT, 1:500 dilution;
Abcam), and phosphatase and tensin homolog (PTEN, 1:500 dilu-
tion; Abcam). After washing, the blots were incubated with horse-
radish peroxidase–conjugated secondary antibodies (GE Healthcare,
Piscataway, NJ) and visualized by ECL Plus Membrane Blot Analysis
detection system (GE Healthcare).
Clonogenic Survival Assays
For clonogenic assays, cells derived from monolayer cultures were
treated with medium containing either 100 nM NPI-0052 (kind gift
of Michael Palladino, Nereus Pharmaceuticals), 10 μM temozolomide
(Sigma), or a combination of both, and placed at 37°C in a humid-
ified atmosphere (5% CO2) for 3 hours. After 3 hours, the medium
was removed, and the cells were enzymatically dissociated with trypsin-
EDTA to produce a single-cell suspension. The cells were counted,
diluted into the desired seeding concentration, and immediately ir-
radiated at room temperature with a cesium (Cs) 137 laboratory ir-
radiator (Mark I, JL Shephard, San Fernando, CA) at a dose rate of
4.95 Gy/min for the time required to generate a dose curve of 0, 2,
4, 6, and 8 Gy. Corresponding controls were sham-irradiated. Colony-
forming assays were performed immediately after irradiation by plat-
ing cells into triplicate 100-mm culture dishes. After 10 to 14 days,
cells were fixed with 75% ethanol and stained with 1% crystal violet,
and colonies containing more than 50 cells were counted. To gener-
ate a radiation survival curve, the surviving fraction at each radia-
tion dose was normalized to that of the sham-irradiated control, and
curves were fitted using a linear-quadratic model (surviving fraction =
e(−αdose − βdose2) [24]. Three independent experiments were performed,
each in triplicates.
Methylthiazolyldiphenyl-Tetrazolium Bromide Assay
A total of 1000 cells derived from the U87MG cell line or each of the
primary GBM lines were plated into white 96-well plates in 50 μl of
DMEM-F12 medium per well. The cells were allowed to adhere over-
night. The next day, the proteasome inhibitor NPI-0052, dissolved
in DMSO and diluted in DMEM-F12, was added at the indicated
concentrations. The control wells were treated with DMEM-F12 me-
dium with DMSO. After 7 to 8 days of incubation with the drug,
20 μl of methylthiazolyldiphenyl-tetrazolium bromide (MTT) reagent
(5 mg/ml in PBS; Sigma) was added to each well. Four hours later,
50 μl of 20% SDS/0.01% HCl solution was added to each well.
The absorbance at 570 nm was measured immediately using a fluores-
cence plate reader (SpectraMax M5).
Animals
Nude (nu/nu), 6- to 8-week-old female mice originally from The
Jackson Laboratories (Bar Harbor, ME), were rederived, bred, and
maintained in a defined flora environment in the Association for As-
sessment and Accreditation of Laboratory Animal Care–accredited
Animal Facilities, of the Department of Radiation Oncology, Uni-
versity of California (Los Angeles, CA), in accordance with all local
and national guidelines for the care of animals. U87MG cells de-
rived from monolayer cultures were injected subcutaneously into
the thighs of nude mice (106 cells per inoculum). The tumor growth
was monitored on a weekly basis, and when the average tumor size
reached approximately 100 mm3, the mice were randomly assigned
to four treatment groups: nontreated (NT), fractionated radiation
(5 × 3 Gy), proteasome inhibitor (NPI-0052), and combination
treatment (5 × 3 Gy + NPI-0052). The mice treated with NPI-
0052 were administered NPI-0052 (0.25 mg/kg) or vehicle alone
(1% DMSO in PBS) intraperitoneally 3 hours before radiation treat-
ment and on days 1, 3, and 5 of radiation treatment. The groups
treated with fractionated radiation were irradiated with 3 Gy for five
consecutive days using a cobalt 60 source (dose rate, 0.6 Gy/min).
The thighs of anesthetized mice bearing the tumor were placed in
a 5 × 5-cm radiation field of the cobalt 60 source while the rest of
the body was shielded.
Results
NPI-0052 Induces Cell Death in Established and Primary
Glioma Cell Lines
NPI-0052 showed a dose-dependent killing of one established gli-
oma cell line, U87MG, and four primary glioma lines, GBM-177,
GBM-2345, GBM-ES, and GBM-RW, in vitro (Figure 1A). In
MTTassays, all of the cell lines had comparable half maximal effective
concentration (EC50) values ranging from 15 (U87MG) to 70 nM
(GBM-2345), except for the GBM-ES glioma line, which had a sig-
nificantly higher EC50 (280 nM). Because radiation is the primary
treatment modality for GBM, we wanted to test the effect of NPI-
0052 on glioma lines in combination with radiation, and given that
Translational Oncology Vol. 3, No. 1, 2010 NPI-0052 and Radiation in Glioma Vlashi et al. 51
postoperative radiotherapy in GBM patients is often accompanied and
followed by treatment with temozolomide, we explored a potential syn-
ergizing effect of NPI-0052 with temozolomide and radiation. First,
all the cell lines were treated for 3 hours with 100 nM NPI-0052 or
10 μM temozolomide, as a single agent or in combination, and clono-
genic survival assays were performed. Also, to characterize their relative
intrinsic radiosensitivity, all the cell lines were irradiated with single
doses of radiation, and clonogenic survival assays were performed.
The acute toxicity to the 3-hour treatment with NPI-0052 and temo-
zolomide, as well as the relative radiosensitivity of all the cell lines
tested, is shown in Figure 1, B and C . Two cell lines (GBM-177
and GBM-RW) were sensitive to temozolomide in the acute toxic-
ity assays, where killing by NPI-0052 dominated (Figure 1B). Sensitiv-
ity to temozolomide seemed to correlate with the higher intrinsic
radiosensitivity of these cell lines (Figure 1, B and C ). Combining
temozolomide and/or NPI-0052 treatments with irradiation showed
that, as single agents, they had little or no radiosensitization effect
(Figure 2, A–E); however, there seemed to be an inverse relationship
between the level of sensitivity to NPI-0052 and the response to com-
bined treatment (Figure 2, A–E). The combination treatment resulted
in a significant radiosensitizing effect of GBM-2345 cell line (Student’s
paired t test: at 2 Gy, P = .01; at 4 Gy, P < .01) and a radioprotective
effect on U87MG (Student’s paired t test: at 2 Gy, P < .01; at 4 Gy, P <
.01; Figure 2, A and E). The other cell lines did not reach statistical
significance for the radiosensitizing effect of the combination treatment
(Figure 2, B–D). However, there seemed to be a trend between the
acute toxicity of NPI-0052 treatment and the radiosensitizing effect
of the combination treatment—the lower the sensitivity of a cell line
to the NPI-0052 treatment, the higher the radiosensitizing effect of
the combination treatment (Figures 1, A and B, and 2, A–E , inserts).
To investigate if the variable response of these cell lines to the dif-
ferent treatments is reflected in their molecular phenotype, we per-
formed Western blots to analyze the expression of EGFR, PTEN,
MGMT, and p53 proteins in each cell line (Figure 3), which reflect
the key pathways altered in glioma [16]. MGMT protein levels
were comparable in all the cell lines, thus different sensitivities to
temozolomide treatment in these cell lines were not reflected by
MGMT protein levels, neither did they correlate with EGFR expres-
sion; the two cell lines (GBM-177 and GBM-RW) that were sensitive
to temozolomide (Figure 1B) did express PTEN (Figure 3). These are
the most radiosensitive cell lines.
There seemed to be a correlative trend between the p53 status of
the glioma cell line (Figure 3) and the radiosensitizing effect of the
combination treatment. The cell lines with wtp53 protein (GBM-
ES, GBM-RW, and U87MG) were not affected by the combination
treatment or, in the case of U87MG, were actually strongly radio-
protected by this treatment (Figures 2, A–C , and 3). In contrast,
the GBM-2345 cell line, which contained higher levels of mutated
Figure 1. NPI-0052 and temozolomide toxicity to glioma cells. (A) U87MG established cell line and four primary glioma cell lines (GBM-ES,
GBM-2345, GBM-177, GBM-RW) were grown as a monolayer in serum conditions. On the day of the experiment, the cells were seeded
into 96-well plates at 1000 cells per well. The cells were allowed to adhere overnight. The next day, the cells were treated with the indicated
concentrations of NPI-0052. At 7 to 8 days later, MTT assays were performed. (B and C) All four cell lines were treated with either 100 nM
NPI-0052 or 10 μM temozolomide 3 hours before being irradiated. The drug was then washed, cells were removed, irradiated with the
indicated doses, and plated at clonal densities. Approximately 3 weeks later, cell colonies were stained and counted. Acute toxicity of NPI-
0052 and temozolomide for all the cell lines was determined (B), and their relative intrinsic radiation sensitivity was compared (C).
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p53 protein, was significantly radiosensitized by the combination
treatment (Student’s paired t test: at 2 Gy, P = .01; at 4 Gy, P <
.01). The GBM-177 cell line, which showed lower levels of the mu-
tant p53 protein (compared with GBM-2345), did not reach statis-
tical significance for the radiosensitizing effect of the combination
treatment; however, there seemed to be a trend toward radiosensiti-
zation (Figures 2, D and E , and 3).
NPI-0052 Does Not Radiosensitize Glioma Xenografts In Vivo
The effect of NPI-0052 in vivo as a single agent or in combina-
tion with fractionated radiation (5 × 3 Gy) was determined using
U87MG xenografts on immunodeficient mice. This cell line was
chosen because treatment with NPI-0052, as a single agent or in
combination with temozolomide, resulted in significant radioprotec-
tion (Figure 2A). To be able to continuously monitor tumor growth,
we implanted U87MG cells (1 × 106 cells/tumor) subcutaneously on
the thighs of nude mice. The tumor-bearing mice were treated intra-
peritoneally (i.p.) with 0.25 mg/kg of NPI-0052 [17] 3 hours before
radiation treatment. Radiation treatment was administered in doses
of 3 Gy for five consecutive days, whereas the NPI-0052 was admin-
istered on days 1, 3, and 5 of radiation treatment. When NPI-0052
was used as a single agent, it delayed U87MG glioma tumor growth
only moderately (Figure 4). The combination of NPI-0052 with
fractionated radiation initially had no effect on tumor growth when
compared with fractionated radiation alone; however, approximately
2 weeks after the end of the treatment, the group treated with the com-
bination regimen did worse than the group treated with fractionated
radiation alone, possibly indicating a radioprotective effect of the
NPI-0052 in this glioma xenograft model (Figure 4). The treatment
dose of 0.25 mg/kg of NPI-0052 resulted in a significant toxicity
in vivo; however, the mice recovered quickly after the administration
of the three NPI-0052 doses (data not shown). It should be noted that
Figure 2. Effect of NPI-0052 and temozolomide treatment on radiation sensitivity of glioma cells. (A–E) Each cell line was grown as a mono-
layer in serum conditions. On the day of the experiment, each cell line was treated with 100 nM of NPI-0052 and/or 10 μM temozolomide
3 hours before radiation treatment. Cells were then trypsinized, counted, irradiated with the indicated doses, and plated at the appropriate
numbers for clonogenic survival assays.
Figure 3.Molecular profile of the glioma cell lines. The established
glioma cell line U87MG and the four primary glioma lines, GBM-177,
GBM-2345, GBM-ES, and GBM-RW, were grown as monolayers in
serum conditions. The cells were removed, lysed, and analyzed for
the expression of p53, MGMT, EGFR, and PTEN proteins through
Western blots.
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the combination treatment with NPI-0052 and temozolomide was
too toxic to the mice (data not shown); therefore, this combination
treatment was not tested in combination with fractionated radiation.
We first used the sub-c glioma xenograft model where the blood-
brain barrier does not represent an obstacle to the drug uptake by the
glioma cells. Given the lack of therapeutic effect of NPI-0052 alone,
or in combination with fractionated radiation in this model, it did not
justify the confirmation of these results in an orthotopic glioma model
where the blood-brain barrier could still be a potential concern.
Discussion
We previously reported that proteasome inhibitors (MG132 and bor-
tezomib) effectively induced cell death in a wide variety of preclinical
cancer models and that the surviving cells were sensitized to ionizing
radiation [18–22]. Surprisingly, bortezomib, another inhibitor of the
26S proteasome, has so far not shown significant clinical antitumor
activity in solid cancers as a single agent or in combination with other
chemotherapeutic drugs [23–25] and failed to synergize with radia-
tion and temozolomide in patients with glioma [10].
Treatment of four primary and one established glioma lines with
NPI-0052 resulted in a dose-dependent induction of cell death with
the primaryGBM lines (GBM-177,GBM-2345,GBM-ES,GBM-RW)
possessing higher EC50 values for NPI-0052 than the established
glioma cell line (U87MG; Figure 1A). A 3-hour treatment with the
drug resulted in a significant reduction in clonogenic survival of all
the cell lines tested (Figure 1B). Overall, the extent of cell killing in
the four primary cell lines and U87MG cells compared well to the ef-
fect of bortezomib in other glioma cell lines [26]. The intrinsic radia-
tion sensitivity of all primary cell lines in vitro varied approximately
two-fold (assessed at 10% survival; Figure 1C ). Temozolomide treat-
ment only affected the clonogenic survival of GBM-177 and GBM-
RW primary glioma lines (Figure 1B), which did not differ in MGMT
expression but differed in p53 status and expressed PTEN protein.
This was in agreement with a previous study reporting that the effect
of temozolomide on GBM cells was not determined by the MGMT
status of the cell alone [27]. Furthermore, a recent report demonstrat-
ing an enrichment of the therapy-resistant side population of cells
by temozolomide [28] does not explain our findings because the in-
terval between drug treatment and plating of the cells was too short
to allow for any selection but was in agreement with our observation
that PTEN-deleted GBMs were insensitive to temozolomide. Inter-
estingly, the two temozolomide-sensitive cell lines were also charac-
terized by the lowest relative intrinsic radiation resistance compared
with the other cell lines, with GBM-ES and U87MG being the most
radiation resistant cell lines. GBM-ES and U87MG cells showed
a shoulder of the survival curve, which indicated an increased abil-
ity to repair DNA damage. PTEN protein expression levels also cor-
related with the relative radioresistance of these cell lines. The two
intrinsically radiation-sensitive cell lines, GBM-177 and GBM-RW,
expressed PTEN protein, whereas the other three cell lines did not.
This is in agreement with other reports demonstrating that loss of
PTEN expression correlates with radioresistance [29,30].
Regardless of their intrinsic radiosensitivity, p53, MGMT, or PTEN
status, temozolomide did not sensitize any of the GMB cell lines to
radiation. This was in disagreement with previous studies show-
ing no radiosensitization of GBM cells by temozolomide [27,31]. In
these studies, cells were exposed to temozolomide for long periods
(24-96 hours), whereas we pretreated the cells with temozolomide
for only 3 hours before irradiation. Therefore, it is possible that longer
incubation with temozolomide would also radiosensitize the GBM
cell lines used in our study. However, given the short half-life of
temozolomide of 1.9 hours [32], we felt that our approach was closer
to the clinical situation in which temozolomide plasma level will peak
after approximately an hour [32].
In clonogenic survival assays, U87MG cells were protected from
radiation by NPI-0052, whereas this drug had only little, if any,
effect on the radiosensitivity of all other GBM cell lines. The mech-
anisms by which proteasome inhibitors can sensitize cancer cells to
radiation are still not well understood. However, the extent of sen-
sitization or even protection of cells by proteasome inhibitors from
cytotoxic agents may depend on the sequence of application [33] and
the microenvironment [19].
Combination of NPI-0052 and temozolomide treatment failed
also to radiosensitize U87MG, GBM-ES, GBM-RW, or GBM-177
cells, but did radiosensitize GBM-2345 cells (Figure 2, A–E ). GBM-
2345 cells have mutated p53 protein and may thus not be arrested in
the G1 phase of the cell cycle where nonhomologous end joining
dominates as DNA double-strand repair mechanism. Treatment with
temozolomide inhibits homologous recombination and thus may only
be effective if a cell relies on homologous recombination to repair DNA
damage [34]. In contrast, U87MG, GBM-RW, and GBM-ES have a
WT p53 and are able to arrest in G1, perform nonhomologous end
joining, and repair their DNA damage, and therefore, temozolomide
is ineffective in these cells. Interestingly, GBM-177 cells, which also
have mutated p53, but express PTEN protein, were also not sensitized
by the combination treatment.
In vivo, the 0.25-mg/kgNPI-0052 dose chosen to be administered i.p.
in these studies is higher than the dose used in other studies where this
drug is also administered i.p. Chauhan [17] used a dose of 0.15mg/kg of
NPI-0052 to test its effect in a multiple myeloma model; however, they
administered this dose twice a week for 5 weeks, whereas our higher
dose of 0.25 mg/kg was only administered a total of three times, thus
justifying the use of a higher dose in hopes of a more optimal effect.
Figure 4. In vivo treatment of U87MG xenografts with NPI-0052 and
radiation. Nude mice with U87MG sub-c tumors were treated with
fractionated radiation (5 × 3 Gy). Three hours before radiation treat-
ment, NPI-0052 was administered at 0.25 mg/kg on days 1, 3, and 5
of the radiation treatment (black arrows). Doted lines denote frac-
tionated radiation schedule (each line symbolizes a dose of 3 Gy).
This is a representative of three independent experiments (n = 5).
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However, NPI-0052 showed a moderate effect on the growth of
U87MG glioma xenografts, and in combination with radiation, it
decreased the efficacy of radiation, which reflected the in vitro situa-
tion [35]. Overall, our results indicate that whereas gliomas in general
were sensitive to NPI-0052–induced cell death, its combination with ra-
diation may have only little effect in a subgroup of gliomas, whereas
others may even be radioprotected by this class of drugs. These results
and a recent study in which resistance of glioma stem cells to proteasome
inhibitors was reported [36], led us to conclude that proteasome inhibi-
tors have only limited, if any, use in the radiotherapy for gliomas and the
increase in overall toxicity may not be justified by the survival benefit
expected from such combination treatment.
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